Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma

Cited by (983)

Items 801–900 of 983

1. Characterization of polyamine metabolism predicts prognosis, immune profile, and therapeutic efficacy in lung adenocarcinoma patients
   Zhouhua Li, Yue Wu, Weichang Yang, Wenjun Wang, Jinbo Li, Xiaotian Huang, Yanqiang Yang, Xinyi Zhang, Xiaoqun Ye · 2024 · Frontiers in Cell and Developmental Biology
2. Brief Report: The Immune Profiles of the Molecular Subtypes of EGFR-Mutant Lung Adenocarcinomas in a Large Real-World Cohort
   Joseph Nicholas Bodor, Joanne Xiu, Vinicius Ernani, Supreet Kaur, Hirva Mansurali Mamdani, Sai‐Hong Ignatius Ou, Patrick C. Ma, Hossein Borghaei, Margie L. Clapper, Ari M. Vanderwalde et al. · 2024 · Clinical Lung Cancer
3. Analyzing the Spatial Distribution of Immune Cells in Lung Adenocarcinoma
   Florina Almarii, Maria Sajin, George Simion, Simona Dima, Vlad Herlea · 2024 · Journal of Personalized Medicine
4. Long-term survival in a patient with Li-Fraumeni syndrome–associated giant cell glioblastoma treated with nivolumab: illustrative case
   Macy Mitchell, Andres Restrepo Orozco, Leonard H. Verhey, Todd W. Vitaz · 2024 · Journal of Neurosurgery Case Lessons
5. Tumor suppressor genotype influences the extent and mode of immunosurveillance in lung cancer
   Keren M. Adler, Haiqing Xu, Amy C. Gladstein, Valerie M. Irizarry-Negron, Maggie R. Robertson, Katherine R. Doerig, Dmitri A. Petrov, Monte M. Winslow, David M. Feldser · 2026 · Nature Communications
6. Concurrent SMARCA4-deficient and poorly differentiated adenocarcinomas in separate lung lobes: a case report and literature review
   Lu Wang, Yinan Wu, Liqian Hu, Gangping Wang · 2025 · World Journal of Surgical Oncology
7. Efficacy and prognostic analysis of chemo-immunotherapy after TKI resistance in EGFR-mutant non-small cell lung cancer with TP53 or KRAS co-mutations
   Yuhui Nie, Chen Song, Kun Wu, Mingxin Yu, Jia Hu, Shuzhen Liu, Hui Fu · 2025 · Frontiers in Immunology
8. Impact of KRAS G12C mutation on the efficacy of chemoradiotherapy in patients with unresectable stage II or III non-small cell lung cancer
   Jean Cabon, D. Lerouge, S. Thureau, Jacques Balosso, Marin Guigo, R. Gervais, Cathérine Dubos, Pascal Dô, Pierre Demontrond, Hubert Curcio et al. · 2025 · Frontiers in Oncology
9. Long-term survival after ALK-TKI resistance through immunotherapy combined with chemotherapy in ALK-positive non-small cell lung cancer: a case report
   Caihong Fu, Lei Yang, Hui Qiao, Xiting Liu, Jiexin Wang · 2025 · Frontiers in Oncology
10. Chemo-Radio-Immunotherapy Strategies to Prevent Immune Resistance in Non-Small Cell Lung Cancer
    Renata Andrea Rusu-Patraulea, Petronela Rusu, Tudor–Eliade Ciuleanu · 2025 · Cancers
11. The potential of MMP14 as a prognostic and immune biomarker in lung cancer
    Jiajia Xiao, Zhenpeng Zhu, Fan Zhang, Xinsheng Wang · 2026 · BMC Cancer
12. Efficacy of first‐line immunochemotherapy across KRAS mutation subtypes in advanced lung adenocarcinoma
    Hongping Jin, H. Huang, Yue Wu, Yidan Zhang, Jianlin Xu, Tengfei Liu, Hua Zhong, Qian Miao, Runbo Zhong · 2026 · International Journal of Cancer
13. TRIM3 Suppresses Tumor Progression in Non-small-Cell Lung Cancer by Promoting PD-L1 Ubiquitination and Degradation
    Wenfa Jiang, Shuchen Chen · 2026 · Annals of Surgical Oncology
14. Single-cell spatial analysis stratifies lung adenocarcinoma with rare actionable mutations and reveals immune-modulatory cellular crosstalk
    Jian Ma, Xin Li, Nian-Song Qian, Shujin Li, Lijun Li, Xiaoxin Zhang, Liqian Su, Yue Yang, Hai-Tao Luo, Ming-Zhu Yin et al. · 2026 · Cell Reports Medicine
15. Influence of oncogenic drivers and signaling pathways on immune checkpoint inhibitor efficacy in NSCLC
    Chunyan Liu, Shan Zhu, Jing Wu, Yuan Qiao, Ning Yang, Jingtao Chen · 2026 · Genes & Diseases
16. KRAS Mutation Subtypes, Co-Mutations, PD-L1 Expression, and Survival Outcomes in Non-Small Cell Lung Cancer
    Nesrin Gürçay, Funda Demirağ, M. Yilmaz, İlknur Öz, Tuba İnal Cengiz, Abdülkadir Koçanoğlu, Serdar Karakaya, Ömer Faruk Demir · 2026 · Journal of Clinical Medicine
17. Altérations moléculaires anciennes et émergentes : quand les rechercher ?
    Xavier Mignard, Anne-Marie Ruppert, Nathalie Rabbe, Gwenaëlle Pontdeme, Martine Antoine, Roger Lacave, A. Lavolé, Jacques L. Cadranel, Marie Wislez · 2017 · Revue des Maladies Respiratoires Actualités
18. Research progress in immune checkpoint inhibitors in the treatment of oncogene-driven advanced non-small cell lung cancer.
    Yuxin Li, Lemeng Zhang, Jianhua Chen · 2020 · PubMed
19. Biomarkers for Immune Checkpoint Inhibitors
    Pouya Mahdavi Sharif, Mahsa Keshavarz‐Fathi, Nima Rezaei · 2020 · Springer eBooks
20. PROS: should immunotherapy be incorporated in the treatment of oncogene-driven lung cancer?
    Alfredo Addeo, Giuseppe Luigi Banna · 2018 · Translational Lung Cancer Research
21. Research Progress of p53 Gene and Tumor
    祥 朱 · 2022 · World Journal of Cancer Research
22. Comprehensive analysis of N6-methyladenosine-related lncRNAs reveals distinct hepatocellular carcinoma subtypes with immunotherapeutic implications.
    Xiaodong Xie, Hongyin Liang, Qing Ruan, Xiao Ma, Chuan Xie, Zhu-lin Luo, Lijun Tang, Long Cheng, Tao Wang · 2022 · PubMed Central
23. Redox-associated messenger RNAs identify novel prognostic values and influence the tumor immune microenvironment of lung adenocarcinoma
    Chen Zhao, Kewei Xiong, Dong Bi, Fangrui Zhao, Yanfang Lan, Xiaorui Jin, Xiangpan Li · 2023 · Frontiers in Genetics
24. Screening and Verification of Key Ubiquitination Genes Related to Immune Infiltration in Stage III/IV Hepatocellular Carcinoma
    Yuhong Tang, Jun Ji Cao, Rui Peng, Xingkang Mao, Bingbing Su, Hao Tang, Daoyuan Tu, Jie Zhou, Guoqing Jiang, Shengjie Jin et al. · 2023 · Journal of Hepatocellular Carcinoma
25. SETBP1 mutation determines sensitivity to immune checkpoint inhibitors in melanoma and NSCLC
    Fengxiao An, Wenjing Zhang, Yuxian Guo, Fuyan Shi, Yujia Kong, Liguo Tang, Caijing Han, Qinghua Wang · 2023 · Aging
26. Single-cell RNA sequencing reveals the effects of anti-PD-L1 therapy on 3LL lung cancer model and its tumor microenvironment
    Hongyu Zhang, Hao Huang, Shaoxian Wu, Xian He, Junjun Chen, Xiao Wei Zheng, Lujun Chen, Zhigang Wang · 2023 · Medical Oncology
27. Histo-Molecular Factors of Response to Combined Chemotherapy and Immunotherapy in Non-Small Cell Lung Cancers
    Marine Marchal, Vincent Leroy, Hélène Béhal, Éric Dansin, Nicolas Paris, Soraya Bordier, Sarah Humez, Fabienne Escande, Clément Gauvain, Alexis Benjamin Cortot · 2023 · Targeted Oncology
28. Identification of immune-related gene signature for non-small cell lung cancer patients with immune checkpoint inhibitors
    Wang Li, Chaonan Han, Chenlei Cai, Jing Wu, Jianing Chen, Chunxia Su · 2024 · Heliyon
29. Clinical Applications of Comprehensive Genomic Profiling in Advanced Non-Small-Cell Lung Cancer—A Case Series
    Chun‐Ming Tsai, Chih-Hung Lin, Yu-Yen Chou, Hsiao‐Yu Jen, Suyog Jain · 2024 · Current Oncology
30. Predictive value and molecular correlates of MYC immunohistochemistry and copy number gain in non-small cell lung carcinomas treated with immunotherapy
    Julia R. Naso, Aakash P. Desai, Caleb Joshua Smith, Yash P. Ashara, Stephen S. F. Yip, Ying‐Chun Lo · 2024 · Lung Cancer
31. Genetic drivers of etiologic heterogeneity in thyroid cancer
    Yon Ho Jee, Nikita V. Pozdeyev, Christopher R. Gignoux, Samantha White, Bryan R. Haugen, Anurag Verma, Raitis Pečulis, Vita Rovīte, Ashley J. Mulford, Alan R. Sanders et al. · 2026 · Nature Communications
32. Continuous remission of single-mode therapy with pembrolizumab plus chemotherapy in locally advanced hypopharyngeal carcinoma: a case report
    Guoning Yu, Jianqiao He, Yingna Gao, Xiaoqiong Shi, Yi Ma, Shicai Chen, Hongliang Zheng, Minhui Zhu, Caiyun Zhang · 2025 · Frontiers in Immunology
33. [A Reflection of the New Wave of Immunotherapy on the Clinical Study of Chinese Lung Cancer Immunotherapy].
    Jingjing Liu, Shuang Zhang, Shuang Li, Ying Cheng · 2017 · Europe PMC (PubMed Central)
34. BRAF: Novel Therapies for an Emerging Target
    Nathaniel James Myall, Sukhmani Kaur Padda · 2019 · Current cancer research
35. Mutation in the kras gene as a predictor of the effectiveness of immunotherapy for non-small cell lung cancer
    Константин Константинович Лактионов, Aleksey M. Kazakov, К. А. Саранцева, D. S. Scherbo, Anastasia P. Koval · 2022 · Siberian Journal of Oncology
36. Neoadjuvant Immunotherapy Combined with Chemotherapy for Local Advanced Non-Small-Cell Lung Cancer in a Patient with a History of Breast Cancer: A Case Report
    Ruixia Yang, Yue Hei, Wenting Zhu, Qianrong Wang, Hongmei Zhang, Yan Chen · 2022 · Current Oncology
37. Complete response to nivolumab in Kirsten rat sarcoma virus oncogene KRAS-G12C mutant metastatic lung adenocarcinoma: a case report
    Jeffrey Mathew Boby, Nadia Ghazali, Anita Mani, Mathew George · 2022 · Journal of Medical Case Reports
38. Identification of a polycomb group-related gene signature for predicting prognosis and immunotherapy efficacy in lung adenocarcinoma
    Lei Liu, Zhanghao Huang, Peng Zhang, Wenmiao Wang, Houqiang Li, Xinyu Sha, Silin Wang, You Lang Zhou, Jiahai Shi · 2023 · Journal of Thoracic Disease
39. Oncogenic RAS Signalling Promotes Tumour Immunoresistance by Stabilising PD-L1 mRNA
    MA Coelho · 2017 · UCL Discovery (University College London)
40. A computational network approach to identify predictive biomarkers and therapeutic combinations for anti-PD-1 immunotherapy in cancer
    Chia-Chin Wu, Yanru Wang, John Andrew Livingston, Jianhua Zhang, P. Andrew Futreal · 2020 · bioRxiv (Cold Spring Harbor Laboratory)
41. Alveolar epithelial type 1 cells serve as a cell of origin for lung adenocarcinoma with distinct molecular and phenotypic presentation
    Minxiao Yang, Hua Min Shen, Per Flodby, Michael D. Koss, Rania Bassiouni, Yixin Liu, Tea Jashashvili, Theresa Ryan Stueve, Daniel J. Mullen, Amy L. Ryan et al. · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
42. Virtual screening to investigate the potential targets and mechanisms of action of "Astragalus-Ligustrum" drug pair in the treatment of non-small cell lung cancer
    Zhengting Deng, Hu Tian, Yuanhua Ding, Qiming Jin, Yichen Liu, Tao Liu, Tong Tao Zhao · 2023 · Research Square
43. Mutations as Predictive Biomarkers for Adenocarcinoma
    Navin R. Mahadevan, Lynette Marie Sholl · 2017 · Molecular pathology library
44. Addictions oncogéniques et immunothérapie : quelle séquence?
    Laurent Mhanna, Julien Mazières · 2019 · Revue des Maladies Respiratoires Actualités
45. Comprehensive and Integrated Genomic Characterization of Human Immunome in Cancer
    Yongsheng Li, Todd Triplett, Brandon Burgman, Ming Sun, Daniel James McGrail, Dan Qi, Sachet Ashok Shukla, Erxi Wu, Catherine J. Wu, Anna Capasso et al. · 2020 · bioRxiv (Cold Spring Harbor Laboratory)
46. Integrated Molecular Characterization of Lung Adenocarcinoma with Implications for Immunotherapy
    Nicholas T. Gimbrone · 2019 · Digital Commons - University of South Florida (University of South Florida)
47. Sex-specific predictive values of biomarkers for immunotherapy efficacy in lung adenocarcinoma
    Mingming Jia, Tian H. Chi · 2020 · bioRxiv (Cold Spring Harbor Laboratory)
48. Ras and Ras Signaling as a Therapeutic Target in Cancer
    Bailee H. Sliker, Paul M. Campbell · 2021 · Elsevier eBooks
49. Viewpoint: The Current Advances and Future Optimization of Blood-based Tumor Mutation Burden as a Biomarker for Cancer Immunotherapy
    Anlin Li · 2021 · Preprints.org
50. Predictive Systems Biomarkers of Response to Immune Checkpoint Inhibitors
    Óscar Lapuente-Santana, Maisa N.G. van Genderen, P.A.J. Hilbers, Francesca Finotello, Federica Eduati · 2021 · SSRN Electronic Journal
51. Predicting the difference in treatment response and survival time of lung adenocarcinoma patients based on a prognostic risk model of glycolysis-related genes
    Rongchang Zhao, Dan Ding, Yan Ding, Rongbo Han, Xiujuan Wang, Chunrong Zhu · 2021 · Research Square
52. In Reply: TP53 Alteration Status and Tumor Mutational Burden Score: Prevalence and Prognosis in Head and Neck Squamous Cell Carcinoma
    Kimberly M. Burcher, Harper L. Wilson, Elena Gavrila, Arianne Abreu, Ralph B D’Agostino, Wei Zhang, Mercedes Porosnicu · 2022 · The Oncologist
53. Understanding the Interplay Between the Tumor Immune Microenvironment and Genetic Alterations in Thoracic Malignancies
    Pasello, Giulia, Emanuela Felley‐Bosco, Remon, Jordi · 2022 · Frontiers research topics
54. Germline cancer gene expression quantitative trait loci influence local and global tumor mutations
    Yuxi Liu, Alexander Gusev, Peter Kraft · 2022 · medRxiv
55. Tumor suppressor p53 deficiency increases tumor immunogenicity through promoting IL33-mediated anti-tumor immune responses
    Yang Li, David Shihong Gao, Lixian Yi, Fei Gao, Runzi Sun, Kevin GuoKai Lu, Junchi Xu, Jason Shoush, Zoi Kykrou, Minxin Liang et al. · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
56. Genetic and Immunological Characterization of Advanced NSCLC with SWItch/Sucrose NonFermentable Families Genetic Alterations and Its Impact on Response to Immune Checkpoint Inhibitors
    Lanlan Pang, Weitao Zhuang, Fei Pang, Lijuan Chen, Jun Liao, Yihua Huang, Tianqin Mao, Ruonan Pei, Yi Lv, Zhaodi Yuan et al. · 2022 · Research Square
57. IGSF6 is a biomarker associated with anti-tumor immune response in lung adenocarcinoma
    Qisi Zheng, Miao Li, Gechen Jiang, Jun Ni, Han Shen, Zhi Zhang, Xinyu Tian · 2022 · Research Square
58. Immunoglobulin superfamily 6-mediated immune signature determines prognosis and immune landscape in lung adenocarcinoma
    Qisi Zheng, Ting Wang, Gechen Jiang, Jun Ni, Zhi Zhang, Xinyu Tian · 2023 · Research Square
59. Predicting therapeutic responses in head and neck squamous cell carcinoma from TP53 mutation and The mutation of TP53 could be detected by cfDNA
    Mei Wei, Yao Liu, Jingtai Zhi, Li Li, Shengchi Zhang, Wei Wang · 2023 · Research Square
60. Prognostic Gene Signature for lung adenocarcinoma with a Higher Risk for Treatment Failure and Accelerated cell cycle and cell proliferation Pathway Activity
    Zhenqing Li, Zheng Li, Yuqi Meng, Xuan Li, Kerong Zhai, Shilin Wei, Bin Li · 2023 · bioRxiv (Cold Spring Harbor Laboratory)
61. Endostar (rh-endostatin) consolidation therapy after sequential chemoradiotherapy in stage III, unresectable lung adenocarcinoma with novel STK11, TP53 and ATM mutations: a case report.
    Ning An, Xiangfeng Jin, Yang Xue · 2023 · PubMed Central
62. Systemic Onco-Sphere: Host Microbiome and Cancer
    Phei Er Saw, Erwei Song · 2023 · Springer eBooks
63. Lymph node and bone metastasis of pulmonary intestinal adenocarcinoma: A case report
    Yanbin Liu, Zeyao Feng, Xinyu Wei, Peizhuo Yao, Xuanyu Liu, Yiwei Jia, Shuqun Zhang, Wanjun Yan · 2023 · Oncology Letters
64. Restoration of Tumor Suppression to Cancer Carrying p53 Mutations
    Mohammad Nurul Amin, Yu Liu · 2023 · IntechOpen eBooks
65. Three novel rare TP53 fusion mutations in a patient with multiple primary cancers: a case report
    Mengyao Lu, Xuemei Zhang, Qian Chu, Yuan Chen, Peng Zhang · 2024 · Oncology and Translational Medicine
66. Case report: The first account of undifferentiated sarcoma with epithelioid features originating in the pleura
    Ling-Xi Xiao, Li Liu, Wang Deng · 2024 · Frontiers in Medicine
67. Genomic Profiling Reveals Immune-Related Gene Differences in Lung Cancer Patients Stratified by PD1/PDL1 Expression: Implications for Immunotherapy Efficacy
    Zhifeng Ye, Ting Hsiang Huang, Keke Hu, Heran Zhou, Ling Huang, Lu Wang · 2024 · Journal of Applied Genetics
68. Important Biomarkers for Better Evaluation of Checkpoint Inhibitors and Other Immunotherapies in Lung Cancer
    Hitesh Malhotra, Anurag Dhiman, Rupesh Kumar Gautam · 2024 · Springer eBooks
69. Identification of lung adenocarcinoma subtypes and a prognostic signature based on activity changes of the hallmark and immunologic gene sets
    Shunkai Zhou, Dehua Zeng, Meiqing Zhang, Mengmeng Chen, Yaming Liu, Qiqiang Chen, Zhen-Ya Lin, Shengsheng Yang, Zhichao Fu, Duohuang Lian et al. · 2024 · Heliyon
70. Additional file 1 of Characterization of genomic instability-related genes predicts survival and therapeutic response in lung adenocarcinoma
    Shuyang Li, Wei Wang, Huihan Yu, Siyu Zhang, Wenxu Bi, Suling Sun, Bo Hong, Zhiyou Fang, Xueran Chen · 2023 · Figshare
71. Additional file 2 of Integrative analysis of TP53 mutations in lung adenocarcinoma for immunotherapies and prognosis
    He Li, Lei Yang, Yuanyuan Wang, Lingchan Wang, Chen, Gang, Li Zhang, Dongchang Wang · 2023 · Figshare
72. Additional file 5 of Establishment and validation of an immune infiltration predictive model for ovarian cancer
    Zhenxia Song, Jingwen Zhang, Yue Sun, Zhongmin Jiang, Xiaoning Liu · 2023 · Figshare
73. Additional file 1 of Genomic features and its potential implication in bone oligometastatic NSCLC
    Rongxin Liao, Guangming Yi, Lu Shen, Xiaoyue Zhang, Zaicheng Xu, Yuan Peng, Zhenzhou Yang · 2023 · Figshare
74. Additional file 2 of A novel immune subtype classification of ER-positive, PR-negative and HER2-negative breast cancer based on the genomic and transcriptomic landscape
    Peiling Xie, Rui Fang An, Shibo Yu, Jianjun He, Huimin Zhang · 2021 · Figshare
75. Comprehensive Analysis of Immune Infiltration Identifies Predictors for Immunotherapy Efficacy in Hepatocellular Carcinoma
    Shaoru Liu, Zongfeng Wu, Yichuan Yuan, Zhu Lin, Dinglan Zuo, Yi Niu, Binkui Li, Yunfei Yuan, Jiliang Qiu · 2024 · Research Square
76. Impact of TP53 mutations on brain metastasis control in non-small cell lung cancer patients undergoing stereotactic radiosurgery.
    Jim X Leng, Chang Su, David James Carpenter, Warren Floyd, Eugene Vaios, Rachel F. Shenker, Peter G. Hendrickson, Will Giles, Trey Carlton Mullikin, Scott Floyd et al. · 2024 · PubMed Central
77. Camrelizumab combined with chemotherapy for stage IV pulmonary sarcomatoid cancer with pancreatic metastases
    Liqin Ruan, Ningbo Fang, Weili Chen, xiaoyong Wu, Xin hua Zhao, Lu Wang · 2024 · Respiratory Medicine Case Reports
78. Let-7a-5p negatively regulates NK1 homeobox 2 gene to influence the progression and prognosis of lung adeno- carcinoma, revealed by bioinformatics analysis
    Jing Xu, Jia Liu · 2022 · New discovery.
79. Molecular Insights Into Actinic Cheilitis and Lower Lip Squamous Cell Carcinoma: AURKA and AURKB Amplifications and Their Association With Tumor Microenvironment
    Vinícius Gonçalves de Souza, Ismael Gomes da Rocha, Sérgio Vitorino Cardoso, Adriano Mota Loyola, Carla Silva Siqueira Miranda, Fábio Morato de Oliveira · 2024 · Journal of Oral Pathology and Medicine
80. Advances in AI-Enhanced Biomedical Imaging for Cancer Immunology
    Willa Wen‐You Yim, Felicia Yu Ting Wee, Zheng Yi Ho, Xinyun Feng, Marcia Zhang, Samuel Lee, Inti Zlobec, Joe Poh-Sheng Yeong, Mai Chan Lau · 2024 · World Scientific Annual Review of Cancer Immunology
81. Identification of Lung Adenocarcinoma Subtypes Based on Nicotinamide Metabolism-Related Genes to Assess Prognosis and Immunotherapy
    Meijun Peng, Qiuli Ding · 2025 · Journal of Environmental Pathology Toxicology and Oncology
82. Precision treatment for human epidermal growth factor receptor 2-amplified advanced rectal cancer: A case report
    Xiao Xia, Qingwen Wang, Zhengyang Zhou, Lei-Sheng Wang, Pei Yu Huang · 2025 · World Journal of Gastrointestinal Oncology
83. Impact of Egfr Gene Status on the Correlation between Egfr and Pd-L1 and Immune Infiltration in Non - Small Cell Lung Cancer
    Dan Wu, Qiong Wang, Xia Sun, Ya Qin, Xiao Liang · 2025 · SSRN Electronic Journal
84. Identification of metabolism-associated molecular classification for effect and prognosis in lung adenocarcinoma based on multidatabases including the cancer genome atlas and gene expression omnibus
    Lilin Que, Zhibing Liu, Yinghui Wu, Lan Luo, Leifeng Liang · 2025 · SAGE Open Medicine
85. Efficacy analysis of targeted P53 therapy in solid tumors
    Pei Wang, Feng Wang · 2025 · Medical Oncology
86. WITHDRAWN: Clinical insights and genetic analysis of pancreatic adenosquamous carcinoma: A case report
    Haodong Qiao, Huaibin Guo, Ze Liang, Lin Kang, Wanxing Zhang · 2025 · Cancer Genetics · Retracted
87. Periphery TH/TS ratio and TP53 mutation predict the efficacy of ICI-based therapy in advanced non-small cell lung cancer with high PD-L1 expression
    Hao Fang, Qing Ma, Linlin Zhang, Diansheng Zhong · 2025 · Research Square
88. Neoadjuvant immunotherapy plus chemotherapy for resectable non-small cell lung cancer with driver mutations: a retrospective analysis
    Junhao Xu, Jinquan Yao, Yuxin Geng, Jie Huang, Bingwen Zou, Xiao Jun Sun, Jin-ming Yu, Feifei Teng · 2025 · Frontiers in Immunology
89. Exploring a mutation-based signature to predict the benefits of immune checkpoint inhibitors in oncogene-addicted subsets of non-small cell lung cancer: a retrospective study
    Jing Ze Huang, Jinsong Lei, Baoyou Xiao, Wenyan Kang, Zhilin Sui, Youjun Deng, Ran Jia, Chujian Huang, Songhua Cai · 2025 · Respiratory Research
90. Genomic pathogenic alterations in the SWI/SNF complex compromise the outcomes of immunotherapy in Chinese patients with KRAS-mutant NSCLC by downregulating STING expression
    Lingling Gao, Jie Jiang, Linlin Zhu, Zhi Xie, Yu Chen, Zhiyi Lv, Yuqing Chen, Wenbin Zhou, Ji Chen, Yumin Zhong et al. · 2025 · BMC Medicine
91. Single-cell and bulk transcriptome analysis reveals the impact of inflammatory microglia on prognosis and immunotherapy response in primary glioblastoma
    Ziadoon Al-yaqoobi, Ya-Ling He, Xiaosheng Wang · 2025 · Clinical & Translational Oncology
92. Additional file 2 of The association of sex-biased ATRX mutation in female gastric cancer patients with enhanced immunotherapy-related anticancer immunity
    Ge, You, Feiran Wei, Guoping Du, Fei, Gaoqiang, Wei Li, Li, Xiaoshan, Chu, Jinjin, Wei, Pingmin · 2021 · Figshare
93. Additional file 3 of A TP53 mutation model for the prediction of prognosis and therapeutic responses in head and neck squamous cell carcinoma
    Shi, Congyu, Liu, Shan, Tian, Xudong, Wang, Xiaoyi, Gao, Pan · 2021 · Figshare
94. Additional file 9 of Molecular subtyping based on immune cell marker genes predicts prognosis and therapeutic response in patients with lung adenocarcinoma
    Liu, Zi-Tao, Shen, Jun-Ting, Lei, Yu-Jie, Huang, Yun-Chao, Zhao, Guang-Qiang, Zheng, Cheng-Hong, Wang, Xi, Wang, Yu-Tian, Chen, Long, Li, Zi-Xuan et al. · 2024 · Figshare
95. Additional file 1 of Molecular subtyping based on immune cell marker genes predicts prognosis and therapeutic response in patients with lung adenocarcinoma
    Liu, Zi-Tao, Shen, Jun-Ting, Lei, Yu-Jie, Huang, Yun-Chao, Zhao, Guang-Qiang, Zheng, Cheng-Hong, Wang, Xi, Wang, Yu-Tian, Chen, Long, Li, Zi-Xuan et al. · 2023 · Figshare
96. Additional file 1 of Development and validation of a VHL-associated immune prognostic signature for clear cell renal cell carcinoma
    Zhang, Jin, Yan, Aiting, Cao, Wei, Shi, Honglei, Cao, Kai, Liu, Xiaowu · 2020 · Figshare
97. Additional file 2 of Molecular subtyping based on immune cell marker genes predicts prognosis and therapeutic response in patients with lung adenocarcinoma
    Liu, Zi-Tao, Shen, Jun-Ting, Lei, Yu-Jie, Huang, Yun-Chao, Zhao, Guang-Qiang, Zheng, Cheng-Hong, Wang, Xi, Wang, Yu-Tian, Chen, Long, Li, Zi-Xuan et al. · 2024 · Figshare
98. Additional file 1 of Identification of comutation in signaling pathways to predict the clinical outcomes of immunotherapy
    Qiu, Jiayue, Li, Xiangmei, He, Yalan, Wang, Qian, Li, Ji, Jiashuo Wu, Ying He Jiang, Junwei Han · 2024 · Figshare
99. Additional file 13 of Molecular subtyping based on immune cell marker genes predicts prognosis and therapeutic response in patients with lung adenocarcinoma
    Liu, Zi-Tao, Shen, Jun-Ting, Lei, Yu-Jie, Huang, Yun-Chao, Zhao, Guang-Qiang, Zheng, Cheng-Hong, Wang, Xi, Wang, Yu-Tian, Chen, Long, Li, Zi-Xuan et al. · 2024 · Figshare
100. Additional file 2 of Identification of comutation in signaling pathways to predict the clinical outcomes of immunotherapy
     Qiu, Jiayue, Li, Xiangmei, He, Yalan, Qian Wang, Li, Ji, Jiashuo Wu, Jiang, Ying, Junwei Han · 2024 · Figshare